Overview

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of fostamatinib compared to placebo on ambulatory blood pressure in patients with active rheumatoid arthritis who are taking a disease-modifying anti-rheumatic drug (DMARD). The study will last for 57 days.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca